Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | S1PR1 | P21453 | 8/20 | 0.34 |
| ▸ | S1PR3 | Q99500 | 7/20 | 0.34 |
| ▸ | PDE4B | Q07343 | 8/20 | 0.33 |
| ▸ | PDE4A | P27815 | 7/20 | 0.33 |
| ▸ | PDE4D | Q08499 | 7/20 | 0.33 |
| ▸ | NPC1 | O15118 | 1/20 | 0.32 |
| ▸ | RAB9A | P51151 | 1/20 | 0.32 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.32 |
| ▸ | HRH3 | Q9Y5N1 | 1/20 | 0.32 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2468369 | 0.91 | S1PR1 (0.35) | S1PR1S1PR3HRH3 | |
| SCHEMBL2458366 | 0.88 | S1PR1 (0.38) | S1PR1S1PR3 | |
| SCHEMBL2472387 | 0.88 | S1PR1 (0.40) | S1PR1S1PR3SMN1; SMN2 | |
| SCHEMBL2460750 | 0.87 | S1PR1 (0.36) | S1PR1S1PR3 | |
| SCHEMBL2458058 | 0.87 | S1PR1 (0.39) | S1PR1S1PR3 | |
| SCHEMBL2460749 | 0.87 | S1PR1 (0.36) | S1PR1S1PR3 | |
| SCHEMBL2456415 | 0.86 | S1PR1 (0.37) | S1PR1S1PR3 | |
| SCHEMBL2458278 | 0.86 | S1PR1 (0.40) | S1PR1S1PR3 | |
| SCHEMBL2463341 | 0.86 | S1PR1 (0.39) | S1PR1S1PR3 | |
| SCHEMBL2473895 | 0.86 | S1PR1 (0.36) | S1PR1S1PR3 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 16 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2455080-A1 | S1P1 receptor agonists for use in the treatment of multiple sclerosis | Almirall, S.A. (ES) | 2012-05-23 | — | — | EP | claimed |
| EP-2455081-A1 | S1P1 receptor agonists for use in the treatment of crohn's disease | Almirall, S.A. (ES) | 2012-05-23 | — | — | EP | claimed |
| US-20110311485-A1 | 1,2,4-OXADIAZOLE DERIVATIVES AND THEIR THERAPEUTIC USE | ALMIRALL S.A. (ES) | 2011-12-22 | — | — | US | claimed |
| EP-2370431-A1 | 1, 2, 4 -OXADIAZOLE DERIVATIVES AND THEIR THERAPEUTIC USE | Almirall S.A. (ES) | 2011-10-05 | — | — | EP | claimed |
| WO-2010072352-A1 | 1, 2, 4 -OXADIAZOLE DERIVATIVES AND THEIR THERAPEUTIC USE | ALMIRALL S.A. (ES) | 2010-07-01 | — | — | WO | claimed |
| EP-2202232-A1 | 1,2,4-oxadiazole derivatives and their therapeutic use | Laboratorios Almirall, S.A. (ES) | 2010-06-30 | — | — | EP | claimed |
| EP-2455080-A1 | S1P1 receptor agonists for use in the treatment of multiple sclerosis | Almirall, S.A. (ES) | 2012-05-23 | — | — | EP | disclosed |
| EP-2455081-A1 | S1P1 receptor agonists for use in the treatment of crohn's disease | Almirall, S.A. (ES) | 2012-05-23 | — | — | EP | disclosed |
| US-20110311485-A1 | 1,2,4-OXADIAZOLE DERIVATIVES AND THEIR THERAPEUTIC USE | ALMIRALL S.A. (ES) | 2011-12-22 | — | — | US | disclosed |
| US-20110311485-A1 | 1,2,4-OXADIAZOLE DERIVATIVES AND THEIR THERAPEUTIC USE | ALMIRALL S.A. (ES) | 2011-12-22 | — | — | US | disclosed |
| US-20110311485-A1 | 1,2,4-OXADIAZOLE DERIVATIVES AND THEIR THERAPEUTIC USE | ALMIRALL S.A. (ES) | 2011-12-22 | — | — | US | disclosed |
| EP-2370431-A1 | 1, 2, 4 -OXADIAZOLE DERIVATIVES AND THEIR THERAPEUTIC USE | Almirall S.A. (ES) | 2011-10-05 | — | — | EP | disclosed |
| WO-2010072352-A1 | 1, 2, 4 -OXADIAZOLE DERIVATIVES AND THEIR THERAPEUTIC USE | ALMIRALL S.A. (ES) | 2010-07-01 | — | — | WO | disclosed |
| WO-2010072352-A1 | 1, 2, 4 -OXADIAZOLE DERIVATIVES AND THEIR THERAPEUTIC USE | ALMIRALL S.A. (ES) | 2010-07-01 | — | — | WO | disclosed |
| EP-2202232-A1 | 1,2,4-oxadiazole derivatives and their therapeutic use | Laboratorios Almirall, S.A. (ES) | 2010-06-30 | — | — | EP | disclosed |
| EP-2202232-A1 | 1,2,4-oxadiazole derivatives and their therapeutic use | Laboratorios Almirall, S.A. (ES) | 2010-06-30 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110311485-A1 | 1,2,4-OXADIAZOLE DERIVATIVES AND THEIR THERAPEUTIC USE | S1PR1, S1PR2, S1PR3 | S1PR1 1/4885S1PR3 3/4885PDE4B 176/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.